Antibody Engineering & Therapeutics Europe - Nicolas Fischer & Sara Majocchi -
Sara Majocchi
Conditional Costimulation of T cells with CD28 Bispecific Antibodies
CD28 bispecific antibodies (bsAbs) provide T cell signal 2 in a TAA-dependent manner. In presence of T cell signal 1, they enhance the induction of T cell proliferation and activation, augment cytokine secretion and boost the T cell-mediated anti-tumoral cytotoxicity. In vitro and in vivo data highlighting how CD28 bsAbs synergize with T cell engagers (which provide T cell activation 1) will be presented.
Immunotherapy and T cell Engagers
Wednesday, 7 June 2023 17:25 - 17:55
Nicolas Fischer
Taking Light Chain Based Bispecific Antibodies to the Clinic
We conceptualized a bispecific antibody format combining a common heavy chain with two different light chains, one kappa and one lambda. κλ body therapeutic candidates have been developed for different indications and two are currently in Phase I clinical trials. Key features of this approach will be discussed, from structural studies to understand light chain driven antigen binding, to GMP manufacturing and early clinical data.
Poised for a Breakthrough: The Emergence of Bispecific and Multispecific Antibodies
Thursday, 8 June 2023 16:15 - 16:45
aa
Digital Experience: All Sessions Live-streamed 6-8 June, 2023
